About the Company
ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NGM News
How a VC and a biotech founder plan to create a new biotech model
Jin-Long Chen and the Column Group are teaming up again, focused on a fresh venture-biotech model to push forward innovative ...
Why NGM Biopharmaceuticals (NGM) Might Surprise This Earnings Season
Investors are always looking for stocks that are poised to beat at earnings season and NGM Biopharmaceuticals, Inc. NGM may be one such company. The firm has earnings coming up pretty soon, and events ...
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
NGM Biopharmaceuticals (NGM) came out with a quarterly loss ... One other stock from the same industry, Aadi Bioscience, Inc. (AADI), is yet to report results for the quarter ended December 2023. The ...
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 ...
NGM Biopharmaceuticals: Q4 Earnings Snapshot
SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — NGM Biopharmaceuticals Inc. (NGM) on Monday reported a loss of $27.7 million in its fourth quarter. On a per-share basis ...
NGM Biopharmaceuticals: Q4 Earnings Snapshot
SOUTH SAN FRANCISCO, Calif. — SOUTH SAN FRANCISCO, Calif. — NGM Biopharmaceuticals Inc. (NGM) on Monday reported a loss of $27.7 million in its fourth quarter. On a per-share basis, the South San ...
Loading the latest forecasts...